Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. The company's mission is to be the global leader in innovating, developing and delivering TIL therapies that harness a patient’s own immune system to recognize and destroy cancer cells unique to each individual. Its lead product Amtagvi, also known as lifileucel, is a one time individualized T cell therapy approved for the treatment of adult patients with previously treated advanced or unresectable metastatic melanoma. Amtagvi is administered as part of a regimen that includes lymphodepletion and a short course of Proleukin, an interleukin 2 product also marketed by Iovance for separate oncology indications. Beyond melanoma, Iovance is advancing its TIL platform in clinical trials for non small cell lung cancer, cervical cancer, endometrial cancer and various sarcoma types. The firm operates a centralized manufacturing facility, the Iovance Cell Therapy Center in Philadelphia, which is the first FDA approved site for commercial TIL cell therapy production and has the capacity to support thousands of patient treatments annually.

Iovance generates revenue primarily from the sale of Amtagvi and Proleukin to healthcare providers and distributors. Amtagvi is sold as a personalized cell therapy product that is manufactured for each patient and administered at authorized treatment centers. Proleukin is sold to 3 main distributors in the United States, to international distributors, and to various third party clients for use in the Amtagvi regimen, for manufacturing processes, and for clinical or research applications. The company also earns revenue from licensing agreements and collaborations related to its TIL technology platform, although product sales constitute the core of its income. Commercial uptake of Amtagvi has been supported by a growing network of authorized treatment centers, real world evidence showing durable responses, and ongoing efforts to secure reimbursement from private and government payors. Iovance anticipates additional revenue streams from potential approvals of Amtagvi in markets such as Canada, the United Kingdom, Australia and Switzerland, as well as from future pipeline candidates that may address larger patient populations in earlier treatment lines.

Iovance occupies a niche within the broader immuno-oncology market as the developer of the first FDA approved TIL cell therapy for a solid tumor cancer. Its competitors include large pharmaceutical companies such as Bristol Myers Squibb, Merck, Pfizer, Roche and Novartis that are advancing checkpoint inhibitor therapies and CAR T cell products, as well as biotechnology firms like BioNtech, Moderna, Regeneron and Immunocore that are pursuing various cell based and cytokine therapies. The company's competitive advantages stem from its autologous TIL approach that targets a broad array of patient specific neoantigens, its scalable centralized manufacturing process at the Iovance Cell Therapy Center, and its extensive intellectual property portfolio which includes more than 330 granted or allowed patents providing exclusivity for Amtagvi through 2042. Additionally, Iovance benefits from orphan drug designations, fast track and regenerative medicine advanced therapy designations that may facilitate regulatory pathways and market exclusivity for its therapies in melanoma and other solid tumor indications. The firm’s strategy focuses on expanding the Amtagvi label to earlier lines of therapy, combining TIL with checkpoint inhibitors in frontline settings, and applying its TIL platform to other high unmet need solid tumors such as non small cell lung cancer and soft tissue sarcoma.

Iovance serves a diverse customer base that includes hospitals, academic and community authorized treatment centers, oncologists and healthcare professionals who administer its TIL therapies, and patients with advanced solid tumor cancers such as melanoma and non small cell lung cancer. The company also sells Proleukin to distributors and third party clients who use the interleukin 2 product in oncology treatment, manufacturing and research settings. While specific customer names are not disclosed in the filing, Iovance reports that its authorized treatment center network spans many sites across the United States and continues to grow as it onboards new academic and community centers in anticipation of regulatory approvals abroad. The firm’s commercial strategy emphasizes educating and training healthcare professionals, collaborating with patient advocacy groups, and working with payors to demonstrate the value of its TIL therapies and secure broad patient access.